(Q50748394)

18 March 2018

title

The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS. (English)

1 reference

18 March 2018

main subject

anti-retroviral agent

0 references

3

R S Hogg

1 reference

18 March 2018

A H Anis

1

1 reference

18 March 2018

D Guh

2

1 reference

18 March 2018

X H Wang

4

1 reference

18 March 2018

B Yip

5

1 reference

18 March 2018

K J Craib

6

1 reference

18 March 2018

M V O'Shaughnessy

7

1 reference

18 March 2018

M T Schechter

8

1 reference

18 March 2018

J S Montaner

9

1 reference

18 March 2018

publication date

1 October 2000

1 reference

18 March 2018

published in

PharmacoEconomics

1 reference

18 March 2018

volume

18

1 reference

18 March 2018

page(s)

393-404

1 reference

18 March 2018

issue

4

1 reference

18 March 2018

https://scigraph.springernature.com/pub.10.2165/00019053-200018040-00007

exact match

0 references

cites work

Cost Effectiveness of Low-Dose Zidovudine Therapy for Asymptomatic Patients with Human Immunodeficiency Virus (HIV) Infection

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00019053-200018040-00007

Cost-effectiveness league tables: More harm than good?

21 January 2018

1 reference

12 December 2020

The economic impact of AIDS in the United States

1 reference

12 December 2020

Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study.

1 reference

12 December 2020

Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

1 reference

12 December 2020

Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy.

1 reference

12 December 2020

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel

1 reference

12 December 2020

Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens

1 reference

12 December 2020

Modelling the Cost Effectiveness of Lamivudine/Zidovudine Combination Therapy in HIV Infection

1 reference

12 December 2020

Interim proposal for a WHO Staging System for HIV infection and Disease

1 reference

12 December 2020

Current controversies in the treatment of HIV infection and AIDS. An economic perspective

1 reference

12 December 2020

The cost-effectiveness of preventing AIDS-related opportunistic infections

1 reference

12 December 2020

1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults

1 reference

12 December 2020

Report from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada

1 reference

12 December 2020

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

1 reference

12 December 2020

Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991.

1 reference

12 December 2020

Progression to AIDS and predictors of AIDS in seroprevalent and seroincident cohorts of homosexual men.

1 reference

12 December 2020

Combination antiretroviral therapy in HIV infection. An economic perspective

1 reference

12 December 2020

Antiviral effect of double and triple drug combinations amongst HIV-infected adults

1 reference

12 December 2020

10.2165/00019053-200018040-00007

Identifiers

DOI

1 reference

18 March 2018

Dimensions Publication ID

1024075285

0 references

Fatcat ID

release_b422rct7yvgs5kvgps7ma2h4x4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b422rct7yvgs5kvgps7ma2h4x4

24 November 2022

mapped directly with Wikidata item

PubMed ID

15344307

1 reference

18 March 2018